Therapeutic potential of miRNAs in Clostridioides difficile infection

Tanya M Monaghan; Christos Polytarchou; Dina Kao; Cameron Alexander; Pratik Gurnani

doi:10.2217/fmb-2021-0311

Therapeutic potential of miRNAs in Clostridioides difficile infection

Future Microbiol. 2022 Mar:17:315-318. doi: 10.2217/fmb-2021-0311. Epub 2022 Feb 17.

Authors

Tanya M Monaghan^{1

2}, Christos Polytarchou^{3

4}, Dina Kao⁵, Cameron Alexander⁶, Pratik Gurnani⁶

Affiliations

¹ National Institute for Health Research Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, NG7 2UH, UK.
² Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, NG7 2UH, UK.
³ Department of Biosciences, John van Geest Cancer Research Centre, School of Science & Technology, Nottingham Trent University, Nottingham, NG11 8NS, UK.
⁴ Centre for Health, Aging & Understanding Disease, School of Science & Technology, Nottingham Trent University, Nottingham, NG11 8NS, UK.
⁵ Department of Medicine, University of Alberta, Edmonton, AB, T6G 2G3, Canada.
⁶ Division of Molecular Therapeutics & Formulation, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK.

PMID: 35172603
DOI: 10.2217/fmb-2021-0311

Abstract

Tweetable abstract Treating Clostridioides difficile infection with miRNAs alone or combined with live biotherapeutic products may augment therapeutic efficacy and help counteract drug resistance in the future.

Keywords: Clostridioides difficile infection; RNA therapeutics; miRNA-based drugs; miRNAs; nanocarriers.

Publication types

Editorial

MeSH terms

Clostridioides
Clostridioides difficile* / genetics
Clostridium Infections* / drug therapy
Humans
MicroRNAs* / genetics
MicroRNAs* / therapeutic use

Substances

MicroRNAs